CAH Cardinal Health, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
15:09
Sep 15
Minervini keeps $CAH long above stop
Holds a slightly profitable long in Cardinal Health, still above his stop level, kept in a light long book rather than being cut during market weakness.
CAH Cardinal Health, Inc. Long 1ST — —
23:55
Sep 02
CNBC
Cardinal Health is a cheap healthcare winner.
Cardinal Health is a high-quality healthcare distributor seeing rotation inflows away from expensive tech; it has been shifting to specialty pharma, generics, and higher-margin businesses, revenue misses stem from drug pricing while its fee-for-service volume model still works, and FY27 guidance implies 13-15% earnings growth at less than 20x earnings, a cheap safe haven.
CAH Cardinal Health, Inc. Long — —
23:44
Jul 01
CNBC
Health insurers and drug distributors are undervalued.
Health insurers and drug distributors deserve to trade higher. Cardinal Health had a great quarter obscured by sector rotation, and CVS gains will be long-lasting.
CAH Cardinal Health, Inc. Long — —
Log in to see ideas

About CAH Investor Commentary

Across the available history and selected sources, Buzzberg tracks CAH (Cardinal Health, Inc.) across 15 sources: 16 bullish vs 0 bearish calls from 21 authors. Historical directional balance: 48% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 33 total trade ideas tracked. Past 7 days, before deduplication: 4 other directions. Latest voices: Mark Minervini, Jim Cramer.